Trial Profile
A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Novel Combination Therapy With Videx (Didanosine), Zerit (Stavudine), Viramune (Nevirapine), and MKC-442 (With or Without Hydroxyurea) for the Treatment of HIV-1 Infection in Non-Nucleoside Reverse Transcriptase Inhibitor Naive Patients Who Failed Previous Protease Inhibitor Treatment
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Didanosine (Primary) ; Stavudine (Primary) ; Emivirine; Hydroxycarbamide; Nevirapine
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 08 Jun 2009 New trial record.